Compulsory Licence for Export
Can a compulsory licence be granted in India solely to export patented medicines?
Latest update: . Case: Hanmi Pharm Co Ltd v Controller General of Patents and Designs. Doctrine: Amendment Before the Controller.
What terms and royalty does the Controller settle in a compulsory licence?
Section 90(1) requires the royalty to be reasonable, and the Controller shall endeavour to secure that the patented articles are made available to the public at reasonably affordable prices.
Doctrine last updated on 14 November 2026
Terms of a Compulsory Licence, Ali on Patents, www.aop.onl/compulsory-licence-terms
1The principles contained in s 90(1)(i) reflect the provisions of the TRIPS Agreement which provides that the ‘right holder shall be paid adequate remuneration in the circumstances of each case, taking into account the economic value of the authorisation’. (TRIPS Agreement, art 31(h).) The Patents Act provides that the royalty and other remunerations due to the patentee should be reasonable having regard to the nature of the invention, the expenditure incurred by the patentee in making the invention or in developing it, in obtaining the patent and keeping it in force, and other relevant factors.
2The Patents Act requires the royalty to be reasonable. (Patents Act 1970, s 11A(7), which provides for ‘reasonable royalty’ to the patent holder where enterprises have made significant investment and were producing and marketing the concerned product prior to 1 January 2005, and continued to manufacture the product covered by the patent on the date of grant of the patent.) For mechanical inventions, the range of royalty varies between 5 to 7 percent. (Shiley Inc’s Patent (1988) RPC 97, p 104. See also Brownie Wireless Co Ltd’s Application (1929) 46 RPC 457; Cassou’s Patent (1971) RPC 91; Extrude Hone Corpn’s Patent (1982) RPC 361; Kalle & Co AG’s Patent [1966] FSR 112; Kamborian’s Patent (1961) RPC 403; Patchett’s Patent (1967) RPC 237; Penn Engineering & Manufacturing Corpn’s Patent (1973) RPC 233.) For pharmaceutical invention, the expenses incurred in research and development of the product must be reasonably covered. It is fair on the part of the patentee to expect a reasonable return on such expenses. (See Re Colbourne Engineering Co’s Application (1955) 72 RPC 169, p 179.) In determing reasonable royalty, the Controller shall consider what a notionally willing licensor and licensee would have agreed upon. (See Du Pont de Nemours & Co (EI) (Blades) Patent (Licence of Right) (1988) RPC 479, pp 489-90; Smith Kline & French Laboratories Ltd’s (Cimetidine) Patent (1990) RPC 203, pp 236; American Cyanamid Co’s (Fenbufen) Patent (1991) RPC 409, pp 411-12.) It is preferable to express royalty as a sum per unit (quantity) of product rather than as a percentage of the selling price of the patentee or the licensee. (Syntex Corpn’s Patent (1986) RPC 585, pp 606; Allen & Hanburys Ltd’s (Salbutamol) Patent (1987) RPC 327, p 359 (CA); Smith Kline & French Laboratories Ltd’s (Cimetidine) Patents (1990) RPC 203, p 245 (CA); Research Corporation’s (Carboplatin) Patent (1990) RPC 663, p 697.) If the rate of royalty is calculated as a percentage of the selling price, the licensee ‘might come into the market at a very low price and thereby fail to return an appropriate royalty to the patentees’. (Syntex Corpn’s Patent (1986) RPC 585, p 596.) The rate of royalty may be subject to indexing to accommodate the changes in the value of money during the term of the licence. (Shiley Inc’s Patent (1988) RPC 97, p 104.)
3The ‘other relevant factors’ mentioned in s 90(1)(i) of the Patents Act can include a variety of things which may differ from case to case. It may include check on quality of goods, sales by an infringer which the patentee himself would not have made, but not the patentee’s position as the manufacturer. (Allen & Hanburys Ltd v Generics (UK) Ltd [1988] FSR 312, p 325 (ECJ).) (Gerber Garment Technology Inc v Lectra Systems Ltd. (1995) RPC 383, pp 412-13.) (See Allen & Hanburys Limited’s (Salbutamol) Patent (1987) RPC 327, p 378 (CA). See also Patchett’s Patent (1967) RPC 237, [1967] FSR 249, p 255.)
4The main object of the grant of compulsory licence is to ensure that the patentable invention is worked in India. Towards this object, the terms and conditions of the licence should be such that it enables the licensee to work the invention to the fullest extent with reasonable profit to him.
5The terms of the licence should enable that the patented articles are made available to the public at affordable prices.
6Normally the licence is granted for the balance term of the invention and will run from the date of the order of the Controller settling the terms and conditions of the licence. (See Allen & Hanburys Ltd v Generics (UK) Ltd (1986) RPC 203 (HL).) The Controller may grant a licence for a shorter term if it is consistent with the public interest. The Controller cannot backdate the grant of a licence. (See Hoffman-La Roche & Co AG v Inter-Continental Pharmaceuticals Ltd (1965) RPC 226, [1965] Ch 795 (CA).)
7The predominant purpose of grant of the licence is to supply the patentable invention in the domestic market. The licensee may also export the patented product in accordance with sub-s (7) of s 84. A licensee may be permitted to export the patented product if the licence is granted to remedy an anti-competitive practice. A decision with regard to a practice being anti-competitive should be made through an appropriate judicial or administrative process. (Patents Act 1970, s 90(1)(ix).)
8Section 92A deals with certain exceptional circumstances under which compulsory licence can be granted for export of pharmaceutical products. The export of a patented article will not amount to an infringement. (Ibid, s 48 details the rights of a patentee with regard to a patent. This does not include export.) But keeping the material or product for export would amount to infringement. (See Smith Kline & French Laboratories Ltd’s (Cimetidine) Patent (1990) RPC 203, pp 225-26.) Hence, the licences for export should also authorise lawful keeping of such products. The Controller has also the power to include ban of exports to protect domestic manufacture as a term of the licence. (See American Cyanamid Co’s (Fenbufen) Patent (1990) RPC 309, pp 328; Research Corpn’s (Carboplatin) Patent (1990) RPC 663, pp 702-03.) The Controller shall not impose restrictions on export if the patentee is not manufacturing in India and does not possess foreign patents in countries in which there is likely to be a market for export from India. Such a restriction would prevent working the patent ’to the fullest extent that is reasonably practicable’. (Patents Act 1970, s 84(7)(d). See also Penn Engineering and Manufacturing Corpn’s Patent (1973) RPC 233, [1972] FSR 533, p 545.) The Controller may impose restrictions on the countries to which the patented product may be exported, like a ban on exports to countries where parallel patents are in force. (See American Cyanamid Co’s (Fenbufen) Patent (1990) RPC 309, p 328.)
9The Controller shall not grant a licence to authorise the licensee to import the patented article from abroad where such importation would constitute an infringement of the rights of the patentee. Under s 48 of the Patents Act, the rights of the patentee will include importing of a patented article into India. The Central Government may direct the Controller to authorise the licensee to import the patented article from abroad for the purpose of public interest. The Central Government may impose conditions with regard to royalty, quantum of import, sale price of imported articles, and the period of importation, before authorising the licensee to import. (Patents Act 1970, s 90(3).)
10Section 91 of the Patents Act deals with cross-licensing by the order of the Controller. The Controller can order the grant of a licence of a patent which is essential for the working of another patent where the patents are possessed by different persons. At any time after the grant of the patent, any person who is entitled to work any other patented invention, either as a patentee or as a licensee, may apply to the Controller for the grant of a licence of the patent not in his possession, on the ground that without a licence he will not be able to work the other invention efficiently. The Controller may order the grant of a licence if he is satisfied that the applicant is able and willing to grant a licence of the invention in his possession on reasonable terms. Additionally, such invention should have made a substantial contribution to the establishment or development of commercial or industrial activity in India.
11If the Controller is satisfied that the conditions for cross-licensing exist, he may make an order granting a licence to the applicant of the other patent. If the proprietor of the other patent requires the patent of the applicant to be licensed, an order to that effect shall be passed by the Controller. However, the licence granted by the Controller shall be non-assignable except with the assignment of the respective patents. The provisions of ss 87, 88, 89 and 90 shall apply mutatis mutandis as they apply to the grant of licences under s 84.
Can a compulsory licence be granted in India solely to export patented medicines?
Can the holder of a compulsory licence assign it or grant sub-licences?
Is Chapter XVI a complete code on abuse of patent rights?
Can a compulsory licence be granted in India because a patented medicine is too expensive?
Doctrine page · Written by Prof. Feroz Ali
www.aop.onl/compulsory-licence-terms